NanoGhost Overview
- Founded
- 2019
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $5M
- Investors
- 1
NanoGhost General Information
Description
Developer of a drug-delivery technology intended to shrink the deadliest forms of cancer by precisely targeting tumors. The company's technology aids in reducing tumor size in small lung carcinoma, prostate and pancreatic cancer tumors, by as much as 85%, enabling patients suffering from cancer to reduce the pain of radiology treatments.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Primary Office
- Haifa
- Israel
NanoGhost Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 23-Dec-2019 | $5M | 000 | 000.00 | Completed | Startup |
NanoGhost Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Marcelle Machluf | Co-Founder | ||
| Yonatan Malca | Co-Founder & Chief Executive Officer |
NanoGhost Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| aMoon Fund | Venture Capital | Minority | 000 0000 | 000000 0 |